Group 1 - The stock of Zhejiang Sitaili Pharmaceutical Co., Ltd. increased by 5.01% on January 21, reaching a price of 11.11 CNY per share, with a trading volume of 150 million CNY and a turnover rate of 3.14%, resulting in a total market capitalization of 4.871 billion CNY [1] - The company, established on September 15, 1997, and listed on March 9, 2016, specializes in the production and sales of non-ionic iodine contrast agents and quinolone raw materials, with the main business revenue composition being 79.73% from contrast agents, 10.19% from other supplementary products, 6.16% from other sources, 2.41% from CMO/CDMO, and 1.52% from quinolone series [1] Group 2 - The Noan Theme Select Mixed Fund (320012) holds 720,100 shares of Sitaili, representing 4.53% of the fund's net value, making it the tenth largest holding. The estimated floating profit for today is approximately 381,600 CNY [2] - The Noan Theme Select Mixed Fund was established on September 15, 2010, with a current size of 173 million CNY. Year-to-date returns are 15.8%, ranking 225 out of 8,844 in its category, while the one-year return is 43.35%, ranking 2,504 out of 8,091. Since inception, the fund has achieved a return of 257.08% [2] Group 3 - The fund manager of the Noan Theme Select Mixed Fund is Luo Chunlei, who has been in the position for 10 years and 121 days. The total asset size of the fund is 173 million CNY, with the best return during the tenure being 130.62% and the worst return being 2.88% [3]

Group 1 - The core viewpoint of the news is that Zhejiang Sitaili Pharmaceutical Co., Ltd. has seen a significant increase in its stock price, with a rise of 5.33% to 11.06 CNY per share, and a total market capitalization of 4.849 billion CNY [1] - The company specializes in the production and sales of non-ionic iodine contrast agents and quinolone raw materials, with the contrast agent series accounting for 79.73% of its main business revenue [1] - The company was established on September 15, 1997, and went public on March 9, 2016 [1] Group 2 - Xiangcai Fund has a significant holding in Sitaili, with its Xiangcai Medical Health Mixed A Fund increasing its stake by 473,300 shares, bringing the total to 659,300 shares, which represents 10.01% of the fund's net value [2] - The fund has achieved a year-to-date return of 43.27%, ranking 1631 out of 8148 in its category [2] - The fund manager, Zhang Quan, has been in charge for 1 year and 318 days, with the best return during his tenure being 66.19% [3]

Core Viewpoint - The stock of Zhejiang Sitaili Pharmaceutical Co., Ltd. experienced a 6.12% increase, reaching 12.65 CNY per share, with a total market capitalization of 5.546 billion CNY as of September 15 [1] Group 1: Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [1] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [1] - The revenue composition of the company includes: contrast agents 79.73%, other supplementary products 10.19%, other 6.16%, CMO/CDMO 2.41%, and quinolone series 1.52% [1] Group 2: Fund Holdings - One fund, Xingye Healthcare A (011466), holds a significant position in Sitaili, with 1.8991 million shares, accounting for 4.83% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.14% and a one-year return of 49.23%, ranking 1872 out of 8246 and 3177 out of 8054 in its category, respectively [2] - The fund manager, Chen Xu, has been in position for 4 years and 193 days, with a total fund size of 385 million CNY [2]